Phase 1b trial in 38 patients with moderate-to-severe ulcerative colitis: PRV-300 vs placebo had more treatment-emergent adverse events (50.0% vs 11.1%; serious 39.3% vs 0%), with 7.1% stopping for AEs; no difference in Mayo score or endoscopic severity.
RCTn = 38
Pokryszka et al. Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE)